Butyrolactol A potentiates caspofungin efficacy against resistant fungi via phospholipid flippase inhibition
Authors:
- Xuefei ChenXCXuefei Chen
- Aline A. FiebigAFAline A. Fiebig
- Zhuyun BianZBZhuyun Bian
Preprint
Abstract
Summary: Fungal infections cause millions of deaths annually and are challenging to treat due to limited therapeutic options and rising resistance. Cryptococci are intrinsically resistant to the latest generation of antifungals, echinocandins, while Candida auris , a notorious global threat, is also increasingly resistant. We performed a natural product extract screen to rescue caspofungin fungicidal activity against Cryptococcus neoformans H99 and identified butyrolactol A, which restores echinocandin efficacy against resistant fungal pathogens, including multidrug-resistant C. auris . Mode of action studies revealed that butyrolactol A inhibits the phospholipid flippase Apt1–Cdc50, blocking phospholipid transport. Cryo-electron microscopy analysis of the Apt1•butyrolactol A complex revealed that the flippase is trapped in a dead-end state. Apt1 inhibition disrupts membrane asymmetry, vesicular trafficking, and cytoskeletal organization, thereby enhancing echinocandin uptake and potency. This study identifies lipid flippases as promising antifungal targets and demonstrates the potential of revisiting natural products to expand the antifungal arsenal and combat resistance.Keywords
All Related Versions
- Published version: Cell, 189 (2), 620.
Funding Information
- Canadian Institutes of Health Research (FDN148463)
- Canadian Institutes of Health Research (PJT190298)
- Canadian Institutes of Health Research (FDN-154288)
- Canadian Institutes of Health Research (FRN 143215)
- Canadian Institutes of Health Research (MOP-119391)
- Canadian Institutes of Health Research (PJT-156067)
- National Institutes of Health (R01CA231466)
- National Institutes of Health (AI39115-27)
- National Institutes of Health (AI050113-20)
- National Institutes of Health (AI170543-02)
- National Institutes of Health (AI172451-02)
- National Institutes of Health (AI133654-07)
- National Institutes of Health predoctoral fellowship (F31 AI150120)
- National Institutes of Health (AI053721-20)
- National Institutes of Health (R01AI127375)
- CIFAR program Fungal Kingdom: Threats & Opportunities (CF-0185)
- CIFAR program Fungal Kingdom: Threats & Opportunities (CF-0116)
- Canada Research Chairs
This publication has 90 references indexed in Scilit:
- Focus on fungiCell, 2024
- Consensus, controversies, and conundrums of P4-ATPases: The emerging face of eukaryotic lipid flippasesJournal of Biological Chemistry, 2024
- Conformational changes of a phosphatidylcholine flippase in lipid membranesCell Reports, 2022
- A Simple Nematode Infection Model for Studying Candida albicans PathogenesisCurrent Protocols in Microbiology, 2020
- Transport Cycle of Plasma Membrane Flippase ATP11C by Cryo-EMCell Reports, 2020
- The putative flippase Apt1 is required for intracellular membrane architecture and biosynthesis of polysaccharide and lipids in Cryptococcus neoformansBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2018
- CryptococcosisInfectious Disease Clinics of North America, 2016
- A Flippase-Independent Function of Atp8b1, the Protein Affected in Familial Intrahepatic Cholestasis Type 1, Is Required for Apical Protein Expression and Microvillus Formation in Polarized Epithelial CellsHepatology, 2010
- Linking phospholipid flippases to vesicle-mediated protein transportBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Identification of 23 complementation groups required for post-translational events in the yeast secretory pathwayCell, 1980